Year: 2023
Type: dissertation
Abstract: Systemic sclerosis (SSc) is an autoimmune-mediated disease characterised by three main features which are vasculopathy, immune dysregulation and fibrosis. Excessive extracellular matrix production - which is the hallmark of fibrosis - appears due to persistent fibroblast activation and leads to severe organ damage and morbidity. Various cell types are involved in the processes that lead to fibrotic tissue remodelling. Elucidating the complex network of cellular interactions is crucial to understand the pathogenesis of the disease and find new efficient targets for its treatment. The aim of this study was to investigate the role of type 2 innate lymphoid cells (ILC2) in fibrotic diseases. It was shown that ILC2s are sufficient to prompt bleomycin-induced lung and skin fibrosis in Rag2-/- Il2rg-/- mice. By single-cell RNA-sequencing, two major populations of ILC2s were identified in experimental lung and skin fibrosis. One highly activated subpopulation of ILC2s was characterised by Gata3 Il1rl1 expression and showed pro-fibrotic features. Moreover, it was shown that this ILC2 subset can interact in a cell contact dependent manner with fibroblasts. Semaphorin 4A (SEMA4A) expressed by ILC2s interacted with Plexin D1 (PLXND1) on fibroblasts and inactivated the polycomb protein EZH2 (enhancer of zeste homolog 2) through p AKT1. The resulting epigenetic changes induced in fibroblasts expression of the transcription factor PU.1, which was recently described as a central regulator of pro-fibrotic gene expression. Signalling through Jagged 1 (JAG1) and Notch receptor 2 (NOTCH2) was identified as a second mechanism of interaction between fibroblasts and ILC2s. JAG1 expressed by fibroblasts activated NOTCH2 signalling in ILC2s, which led to expression of the pro-fibrotic cytokine interleukin-13 (IL-13). Furthermore, this interaction stabilized interleukin-9 receptor (IL-9R) expression and enabled a chronic response to elevated IL-9 levels during fibrotic remodelling. The second population of ILC2s showed high expression of Icos as well as several markers of immature ILC2s. This progenitor-like ILC2 subset was actively recruited from the bone marrow to the fibrotic tissue. Moreover, expression of the TNF superfamily ligand 1A (TL1A) by damaged endothelial cells activated IL-9 expression, which acted in an autocrine loop in those immature ILC2s. IL-9 stimulation caused increased levels of cellular reactive oxygen species (ROS) in ICOS+ ILC2s, which led to changes in gene expression and therefore differentiation into pro-fibrotic ILC2s characterised by ST2, NOTCH2 and SEMA4A expression. In conclusion, the study offers new insights into ILC2 phenotypes, the role of IL-9 on ILC2 differentiation and ILC2 interaction with endothelial cells and fibroblasts in fibrotic diseases. ILC2s are identified as an important link between vasculopathy and fibroblast activation in fibrotic diseases. As effective anti-fibrotic therapies are still missing, the findings of this study might provide new ideas for future therapeutic targets.
Author: Weber, Stefanie Katharina
Institution: Friedrich-Alexander-Universität Erlangen-Nürnberg
Language: German
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W6997003766
